Trial reportBritish journal of clinical pharmacology2005
Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate.
Trial report in British journal of clinical pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.Antimicrobial agents and chemotherapy · 2014Trial
- Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.Antimicrobial agents and chemotherapy · 2011Trial
- Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.PloS one · 2008Trial
- Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system.PloS one · 2025Article
- Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects.Pharmaceutics · 2024Article
- Sources of Interindividual Variability.Methods in molecular biology (Clifton, N.J.) · 2021Article
- An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline.Antimicrobial agents and chemotherapy · 2020Article
- Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug.BMC nephrology · 2014Article
- The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.European journal of clinical pharmacology · 2013Article
- The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.British journal of clinical pharmacology · 2012Review
- Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.Antimicrobial agents and chemotherapy · 2011Article
- Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Advances in therapy · 2011Review
- Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.Paediatric drugs · 2011Review
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
- Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.The Journal of antimicrobial chemotherapy · 2010Review
- Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2010Article
- Antivirals for the treatment and prevention of epidemic and pandemic influenza.Influenza and other respiratory viruses · 2007Review
- Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.Antimicrobial agents and chemotherapy · 2006Article
Corrections and comments
- Erratum issuedDosage error in article text
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in hepatically impaired patients and healthy subjects.
methodsHepatically impaired patients (n = 11) and healthy subjects (n = 11) were individually paired on the basis of gender, age (+/-10 years) and body weight (+/-20%) and administered a single dose of oseltamivir (75 mg).
resultsOseltamivir and oseltamivir carboxylate C(max) were < or =6% and < or =19% lower, and their AUC(0,infinity) 33% higher and < or =19% lower, respectively, in hepatically impaired patients compared with healthy subjects. These changes are within the safety limits for the drug.
conclusionsThe metabolism of oseltamivir is not compromised [corrected] in hepatically impaired patients. No dose adjustment is required in these patients when receiving oseltamivir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.